Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

342
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
342
Tumor Immunotherapy01:27

Tumor Immunotherapy

488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes.

Molecular therapy. Oncology·2026
Same author

Lamina dura thickening in patients on antiresorptive therapy as a radiographic risk indicator of MRONJ: a retrospective longitudinal cohort study.

Dento maxillo facial radiology·2026
Same author

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.

Frontiers in oncology·2026
Same author

Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis.

Nature genetics·2026
Same author

Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective analysis.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Cancer research communications·2026

Related Experiment Video

Updated: Jun 10, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.8K

Trial watch: anticancer vaccination with dendritic cells.

Francisca Borges1, Raquel S Laureano1, Isaure Vanmeerbeek1

  • 1Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.

Oncoimmunology
|October 14, 2024
PubMed
Summary

Dendritic cell (DC) vaccines show promise for cancer treatment by stimulating immune responses. However, their effectiveness is limited by the tumor microenvironment, prompting research into combination therapies for enhanced anticancer immunity.

Keywords:
Antigen cross-presentationDAMPsT cell primingTAAsclinical trialdendritic cellsimmune checkpoint blockerstumor-infiltrating lymphocytes

More Related Videos

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.4K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.2K

Related Experiment Videos

Last Updated: Jun 10, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

11.8K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.4K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.2K

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Dendritic cells (DCs) bridge innate and adaptive immunity, making them key targets for cancer vaccine development.
  • Current DC-based immunotherapies involve ex vivo maturation and antigen pulsing of patient-derived DCs for T-cell activation.
  • Clinical efficacy of DC vaccines is often hindered by the immunosuppressive tumor microenvironment.

Purpose of the Study:

  • To review recent advancements in DC-based cancer treatments.
  • To explore strategies for enhancing DC vaccine immunogenicity.
  • To discuss the future role of DC vaccines in immuno-oncology.

Main Methods:

  • Summary of preclinical and clinical strategies in DC-based cancer therapy.
  • Analysis of combination therapies with T cell-targeting immunotherapies.
  • Review of recent literature on DC vaccine development.

Main Results:

  • DC-based vaccines can elicit potent tumor-specific immune responses.
  • Combination therapies are being explored to overcome the immunosuppressive tumor microenvironment.
  • New preclinical and clinical strategies are emerging to improve DC vaccine efficacy.

Conclusions:

  • DC-based vaccines hold significant potential in cancer immunotherapy.
  • Overcoming the immunosuppressive tumor microenvironment is crucial for clinical success.
  • Future research focuses on optimizing DC vaccines and combining them with other immunotherapies for improved anticancer outcomes.